Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

被引:313
作者
Cooper, Alissa J. [1 ]
Sequist, Lecia, V [1 ]
Lin, Jessica J. [1 ]
机构
[1] Massachusetts Gen Hosp, Dept Med, Canc Ctr, Boston, MA 02114 USA
关键词
CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ANAPLASTIC LYMPHOMA KINASE; FACTOR RECEPTOR EGFR; PHASE-II TRIAL; BIM DELETION POLYMORPHISM; ACQUIRED-RESISTANCE; OPEN-LABEL; ADVANCED NSCLC; MUTANT NSCLC;
D O I
10.1038/s41571-022-00639-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with non-small-cell lung cancers (NSCLCs) harbouring oncogenic EGFR or ALK alterations can benefit from therapies targeting these alterations, although acquired resistance to these agents is common. Third-generation inhibitors have extended the response durations of many patients with NSCLCs harbouring these alterations, albeit with differing patterns of resistance to those associated with earlier-generation agents. Here, the authors describe the mechanisms of acquired resistance to third-generation EGFR and ALK inhibitors and provide insights into future research directions in this area. The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment paradigm for patients with advanced-stage disease. Numerous EGFR and ALK tyrosine kinase inhibitors (TKIs) with demonstrated efficacy in patients with EGFR-mutant and ALK-rearranged NSCLCs have been developed, culminating in the availability of the highly effective third-generation TKIs osimertinib and lorlatinib, respectively. Despite their marked efficacy, resistance to these agents remains an unsolved fundamental challenge. Both 'on-target' mechanisms (largely mediated by acquired resistance mutations in the kinase domains of EGFR or ALK) and 'off-target' mechanisms of resistance (mediated by non-target kinase alterations such as bypass signalling activation or phenotypic transformation) have been identified in patients with disease progression on osimertinib or lorlatinib. A growing understanding of the biology and spectrum of these mechanisms of resistance has already begun to inform the development of more effective therapeutic strategies. In this Review, we discuss the development of third-generation EGFR and ALK inhibitors, predominant mechanisms of resistance, and approaches to tackling resistance in the clinic, ranging from novel fourth-generation TKIs to combination regimens and other investigational therapies.
引用
收藏
页码:499 / 514
页数:16
相关论文
共 273 条
[1]   Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].
Ahn, M. -J. ;
Yang, J. ;
Yu, H. ;
Saka, H. ;
Ramalingam, S. ;
Goto, K. ;
Kim, S. -W. ;
Yang, L. ;
Walding, A. ;
Oxnard, G. R. .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115
[2]   Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial [J].
Ahn, Myung-Ju ;
Cho, Byoung Chul ;
Ou, Xiaoling ;
Walding, Andrew ;
Dymond, Angela W. ;
Ren, Song ;
Cantarini, Mireille ;
Janne, Pasi A. .
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) :718-723
[3]   CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma [J].
Ait-Tahar, Kamel ;
Barnardo, Martin C. N. ;
Pulford, Karen .
CANCER RESEARCH, 2007, 67 (05) :1898-1901
[4]   B and CTL responses to the ALK protein in patients with ALK-positive ALCL [J].
Ait-Taharl, K ;
Cerundolo, V ;
Banham, AH ;
Hatton, C ;
Blanchard, T ;
Kusec, R ;
Becker, M ;
Smith, GL ;
Pulford, K .
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (03) :688-695
[5]   Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial [J].
Akamatsu, Hiroaki ;
Toi, Yukihiro ;
Hayashi, Hidetoshi ;
Fujimoto, Daichi ;
Tachihara, Motoko ;
Furuya, Naoki ;
Otani, Sakiko ;
Shimizu, Junichi ;
Katakami, Nobuyuki ;
Azuma, Koichi ;
Miura, Naoko ;
Nishino, Kazumi ;
Hara, Satoshi ;
Teraoka, Shunsuke ;
Morita, Satoshi ;
Nakagawa, Kazuhiko ;
Yamamoto, Nobuyuki .
JAMA ONCOLOGY, 2021, 7 (03) :386-394
[6]   Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion [J].
Allen, Justin M. ;
Schrock, Alexa B. ;
Erlich, Rachel L. ;
Miller, Vincent A. ;
Stephens, Philip J. ;
Ross, Jeffrey S. ;
Ou, Sai-Hong Ignatius ;
Ali, Siraj M. ;
Vafai, Davood .
CLINICAL LUNG CANCER, 2017, 18 (03) :E219-E222
[7]  
[Anonymous], 2016, Cancer Discov, V6, pOF7, DOI [10.1158/2159-8290.CD-NB2016-044, 10.1158/2159-8290.CD-NB2016-076]
[9]  
[Anonymous], 2021, The Human Protein Atlas
[10]  
Apostolou P, 2018, ANN ONCOL, V29